Propranolol's Impact on Liver Function in Cirrhotic Patients

Monitoring and Dose Adjustment

In cirrhotic patients, careful consideration of risks and benefits is needed when administering non-selective beta-blockers like propranolol, according to the Clinical and Molecular Hepatology guidelines 1, 2
Maximum recommended doses should be reduced in patients with cirrhosis with ascites (160 mg daily) compared to those without ascites (320 mg daily), as recommended by the Clinical and Molecular Hepatology guidelines 1, 2

Discontinuation of propranolol in cirrhotic patients can increase the risk of variceal bleeding and mortality, so treatment should be continued indefinitely unless contraindicated, as advised by the Clinical and Molecular Hepatology guidelines 2, 3
If propranolol must be discontinued in patients with varices due to adverse effects, alternative treatments such as endoscopic variceal ligation (EVL) should be considered, according to the Clinical and Molecular Hepatology guidelines 2, 3

In patients with refractory ascites, low-dose propranolol (80 mg/day) may be safer than higher doses, as suggested by the Clinical and Molecular Hepatology guidelines 2
In patients with end-stage liver disease, particularly those with refractory ascites or spontaneous bacterial peritonitis, close monitoring of blood pressure and renal function is essential, as recommended by the Clinical and Molecular Hepatology guidelines 2, 3